CL2008002093A1 - Compuestos derivados de piperazinona y tiadiazinona, antagonistas de los receptores ccr2, ccr3 y ccr5; proceso de preparacion de estos; composicion farmaceutica que los comprende; uso para tratar enfermedades como, artritis reumatoide, isquemia, asma, entre otras. - Google Patents

Compuestos derivados de piperazinona y tiadiazinona, antagonistas de los receptores ccr2, ccr3 y ccr5; proceso de preparacion de estos; composicion farmaceutica que los comprende; uso para tratar enfermedades como, artritis reumatoide, isquemia, asma, entre otras.

Info

Publication number
CL2008002093A1
CL2008002093A1 CL2008002093A CL2008002093A CL2008002093A1 CL 2008002093 A1 CL2008002093 A1 CL 2008002093A1 CL 2008002093 A CL2008002093 A CL 2008002093A CL 2008002093 A CL2008002093 A CL 2008002093A CL 2008002093 A1 CL2008002093 A1 CL 2008002093A1
Authority
CL
Chile
Prior art keywords
preparing
pharmaceutical composition
ischemia
thiadiazinone
piperazinone
Prior art date
Application number
CL2008002093A
Other languages
English (en)
Inventor
Mattei Patrizio
Binggeli Alfred
Aebi Johannes
Green Luke
P Maerki Hans
Ricklin Fabienne
Hartmann Guido
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2008002093A1 publication Critical patent/CL2008002093A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Compuestos derivados de piperazin-2-ona; procedimiento de preparación de dichos compuestos; composición farmacéutica que contiene a dichos compuestos; y su uso para el tratamiento y/o profilaxis de enfermedad oclusiva de arterias periféricas, isquemia crítica de extremidades, entre otras.
CL2008002093A 2007-07-19 2008-07-17 Compuestos derivados de piperazinona y tiadiazinona, antagonistas de los receptores ccr2, ccr3 y ccr5; proceso de preparacion de estos; composicion farmaceutica que los comprende; uso para tratar enfermedades como, artritis reumatoide, isquemia, asma, entre otras. CL2008002093A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07112766 2007-07-19

Publications (1)

Publication Number Publication Date
CL2008002093A1 true CL2008002093A1 (es) 2009-05-29

Family

ID=39810251

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002093A CL2008002093A1 (es) 2007-07-19 2008-07-17 Compuestos derivados de piperazinona y tiadiazinona, antagonistas de los receptores ccr2, ccr3 y ccr5; proceso de preparacion de estos; composicion farmaceutica que los comprende; uso para tratar enfermedades como, artritis reumatoide, isquemia, asma, entre otras.

Country Status (15)

Country Link
US (1) US8063042B2 (es)
EP (1) EP2220055A2 (es)
JP (1) JP2010533672A (es)
KR (1) KR20100033544A (es)
CN (1) CN101754957A (es)
AR (1) AR067574A1 (es)
AU (1) AU2008277796A1 (es)
BR (1) BRPI0814424A2 (es)
CA (1) CA2695998A1 (es)
CL (1) CL2008002093A1 (es)
PE (1) PE20090482A1 (es)
RU (1) RU2010105682A (es)
TW (1) TW200911259A (es)
WO (1) WO2009010429A2 (es)
ZA (1) ZA201000353B (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150567B2 (en) 2009-10-01 2015-10-06 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US9241924B2 (en) 2010-06-23 2016-01-26 Cymabay Therapeutics, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP2185544B1 (en) 2007-07-19 2014-11-26 Cymabay Therapeutics, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 for the treatment of diabetes and metabolic disorders
JP5368556B2 (ja) 2008-07-16 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー 心臓血管疾患の処置のための新規ヘテロシクリル化合物
US8471004B2 (en) 2009-10-07 2013-06-25 Hoffman-La Roche Inc. Bicyclic compounds
US8445674B2 (en) * 2009-10-21 2013-05-21 Hoffmann-La Roche Inc Heterocyclyl compounds
US8486967B2 (en) * 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
CN109862896A (zh) 2016-08-03 2019-06-07 西玛贝医药公司 用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
CN107098850A (zh) * 2017-05-25 2017-08-29 西安近代化学研究所 一种合成1‑甲基‑3‑硝基‑4‑苯基‑2,6‑二哌啶酮的方法
EP3883634A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN111423454B (zh) * 2020-04-24 2021-06-22 苏州大学 哌嗪类化合物及其在制备趋化因子受体ccr2拮抗剂中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637271A (es) * 1963-04-04 1900-01-01
GB1218591A (en) * 1968-04-03 1971-01-06 Delalande Sa Derivatives of n-(3,4,5-trimethoxy cennamoyl) piperazine and their process of preparation
FR2522325B1 (fr) * 1982-02-26 1985-08-09 Delalande Sa Nouveaux derives aryliques de la piperazine, de l'homopiperazine et de n,n'-dialkyl diamino-1,2 ethane, leur procede de preparation et leur application en therapeutique
ZA99607B (en) * 1998-01-27 1999-07-27 Rhone Poulenc Rorer Pharma Substituted oxoazaheterocyclyl factor xa inhibitors.
US6974869B2 (en) * 2001-09-18 2005-12-13 Bristol-Myers Squibb Pharma Company Piperizinones as modulators of chemokine receptor activity
US7977346B2 (en) * 2006-01-17 2011-07-12 Guoqing Paul Chen Spiro compounds and methods of use

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150567B2 (en) 2009-10-01 2015-10-06 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US9241924B2 (en) 2010-06-23 2016-01-26 Cymabay Therapeutics, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US10098843B2 (en) 2010-06-23 2018-10-16 Cymabay Therapeutics, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine

Also Published As

Publication number Publication date
AR067574A1 (es) 2009-10-14
US20090023713A1 (en) 2009-01-22
WO2009010429A3 (en) 2009-04-30
CA2695998A1 (en) 2009-01-22
EP2220055A2 (en) 2010-08-25
ZA201000353B (en) 2013-06-26
CN101754957A (zh) 2010-06-23
JP2010533672A (ja) 2010-10-28
AU2008277796A1 (en) 2009-01-22
KR20100033544A (ko) 2010-03-30
BRPI0814424A2 (pt) 2015-01-06
RU2010105682A (ru) 2011-08-27
TW200911259A (en) 2009-03-16
US8063042B2 (en) 2011-11-22
PE20090482A1 (es) 2009-05-09
WO2009010429A2 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
CL2008002093A1 (es) Compuestos derivados de piperazinona y tiadiazinona, antagonistas de los receptores ccr2, ccr3 y ccr5; proceso de preparacion de estos; composicion farmaceutica que los comprende; uso para tratar enfermedades como, artritis reumatoide, isquemia, asma, entre otras.
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
SV2011003903A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes
CL2011002185A1 (es) Compuestos n,n-dimetil-5-(2-metil-6-((5-metilpirazin-2-il)-carbamoil)benzofuran-4-iloxi)pirimidin-2-carboxamida y sus sales; composicion farmaceutica que los comprende; y su uso como activadores de la glucoquinasa para tratar la obesidad y para tratar o retrasar la progresion o el comienzo de la diabetes de tipo 2 y trastornos relacionados.
CL2014003388A1 (es) Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades.
DOP2009000133A (es) Derivados de indol como agonistas de los receptores s1p1
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
UY29839A1 (es) Ácidos fenoxiaceticos sustituidos, composiciones farmacéuticas conteniéndolos, procesos para su preparación y aplicaciones.
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
ECSP088891A (es) Derivados bicíclicos como inhibidores de cetp
SV2006002098A (es) Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central ref. pc32250a
CL2008000690A1 (es) Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
CL2007002492A1 (es) Compuestos derivados de bi-,tri o policiclos no aromaticos, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; proceso de preparacion de estos; composicion famaceutica que los comprende; uso en el tratamiento de enfermedades tales como la obesidad, diabetes y dislipidemia, entre otras.
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
CL2007003666A1 (es) Compuestos derivados del acido nicotinico; composicion farmaceutica que comprende a dichos compuestos; combinacion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis, esclerosis multiple, psoriasis, entre otras.
ECSP13012573A (es) 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3
PA8842101A1 (es) Heteroarilos sustituidos
CL2008001671A1 (es) Compuestos derivados de piperidina/piperazina inhibidores de dgat1, composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades metabolicas especialmente diabetes.
CL2007003191A1 (es) Compuestos derivados de pirimido-piridona, inhibidores de las proteina quinasas; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como artritis, sindrome de colon irritable, sindrome disneico agudo del adulto, epoc y para el
CL2008000641A1 (es) Compuestos derivados de amidas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del insomnio, disfuncion sexual, esquizofrenia, entre otras enferme
CL2009000964A1 (es) Compuestos derivados de 1-aril-2-imino-1,2-dihidropiridina-3-carboxamida, antagonista del receptor adrenergico alfa 1d, composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de enfermedades del tracto urinario inferior.
CL2007003223A1 (es) Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades.